Product
Lenvatinib + Cadonilimab
1 clinical trial
1 indication
Indication
Hepatocellular Carcinoma Non-resectableClinical trial
A Phase 2, Open-label, Single Arm Study of Combined HAIC, Lenvatinib and Cadonilimab as Conversion Therapy for Unresectable Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2025-12-31